.
MergerLinks Header Logo

Announced

Completed

Gilead Sciences completed the acquisition of MiroBio from Monograph for $405m.

Financials

Edit Data
Transaction Value£333m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Majority

biotechnology company

Biotechnology

Cross Border

Private

therapeutics

Acquisition

Friendly

Single Bidder

United Kingdom

Private Equity

Completed

Synopsis

Edit

Gilead Sciences, an American biopharmaceutical company, completed the acquisition of MiroBio, a biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, from Monograph, a fund manager, for $405m. “We are excited to be joining Gilead. MiroBio has a deep understanding of checkpoint receptor signaling and a proprietary approach to select and generate superior agonist antibodies. Combining this with Gilead’s drug development and therapeutic area expertise will allow us to fully explore the potential of checkpoint agonist antibodies for patients with autoimmune disease," Eliot Charles, MiroBio Chairman.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US